alkermes.comAlkermes – A Global Biopharmaceutical Company

Discover Alkermes Our Values Leadership Diversity, Inclusion & Belonging Awards and Recognition Collaborations Locations Medicines & Focus Our Focus Disease Areas Innovative Medicines Third-Party Medicines Research & Development Pipeline Technologies & Capabilities Research & Medical Grants Clinical Trials Early Access Responsibility Corporate Responsibility Patient Engagement & Advocacy Alkermes Inspiration Grants ℠ Corporate Giving Corporate Responsibility Reports Public Policy Investors Press Releases Investor Events / Presentations SEC Filings Annual Reports Corporate Governance Stock Information Investor Resources Email Alerts News & Events Press Releases Our Stories Media Resources Statements Contact Us Careers Working Here Our Culture Benefits Join Our Team Great Science Deep Compassion Real Impact Leveraging our long-standing neuroscience expertise to develop medicines that make a difference. Discover Alkermes Featured News May 14, 2024 Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences Read more May 02, 2024 Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk Read more May 01, 2024 Alkermes plc Reports First Quarter 2024 Financial Results Read more See all press releases Responsible Growth We think broadly about our commitment to responsible environmental stewardship, and strive to reduce the impact of our operations on the environment. We also seek to foster a collaborative culture that promotes the health, safety and well-being of our employees. View Corporate Responsibility report Inspiring Inclusion In celebration of International Women’s Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion. Read the reflections United in Purpose Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and commitment to excellence are the cornerstone of our success. Explore career opportunities R&D Pipeline We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates. Click to view our interactive pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Olanzapine and samidorphan Schizophrenia and Bipolar I Disorder (Pediatric) Phase 3 Overview Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S. Clinical Trials Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064 . ALKS 2680 Narcolepsy Type 1 Phase 2 Narcolepsy Type 2 Phase 1 Overview ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy. Clinical Trials ALKS 2680 is currently being evaluated in the Vibrance-1 phase 2 study in adults with narcolepsy type 1. For more information about this study, please visit vibrancestudies.com (for U.S. audiences only) and clinicaltrials.gov/study/NCT06358950 . ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers, and in adults with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. Orexin Agonists Neuroscience Indications Discovery Overview Additional orexin 2 receptor agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders. These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority. L ast updated: April 2024 Careers We dare for progress every day. We take pride in our unique and compassionate spirit. Our shared mission to make a real impact for others drives our purpose. With collaboration at our core, we believe that anything is possible. Working at Alkermes Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We are driven to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases. Contact Us Terms of Use Privacy Policy Sitemap © 2024 Alkermes. All rights reserved. Close You are now leaving Alkermes.com. Alkermes assumes no responsibility for information or statements on external websites. Agree Go...